Supplementary Table S2 from Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial

Authors:

Open Access

Publisher website

25 November 2025

other
Published by American Association for Cancer Research (AACR)

DOI:10.1158/1078-0432.30707864

Abstract

Representativeness of Study Participants

Keywords